Enforcement tracker
FDA warning letters to peptide sellers
10 letters, newest first. Each row links to the letter itself on fda.gov. A warning letter is FDA's stated position, not a court finding; see what a warning letter means.
Latest letter in this list: · Built from the dated facts in our vendor status log
2026
7 letters| Date | Seller | What the letter says | Status log |
|---|---|---|---|
| NuScience Peptidesnusciencepeptides.com | FDA warning letter 733652 following a July 2026 review of nusciencepeptides.com. Read the letter on fda.gov | Site responding; FDA warning letter Aug 24 2026 | |
| Peak Performance Peptidespppepz.com | FDA warning letter 735127 following a July 2026 review of pppepz.com. Read the letter on fda.gov | Site responding; FDA warning letter Aug 24 2026 | |
| Peptide Partnerspeptide.partners | FDA warning letter 735063: “GLP-1 S (Semaglutide),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta (Retatrutide),” “SS-31 (Elamipretide),” “Tesa Peptide (Tesamorelin),” “PT-141 (Bremelanotide)” and “Reconstitution Solution (BAC)” called unapproved new drugs. Response requested within 15 business days. Read the letter on fda.gov | Site responding; FDA warning letter Aug 24 2026 | |
| Royal Peptidesroyal-peptides.com | FDA warning letter 734884: seven products called unapproved new drugs under section 505(a). Read the letter on fda.gov | Site responding; FDA warning letter Aug 24 2026 | |
| Tex Peptides (TXP Innovations LLC)texpeptide.com | FDA warning letter 735067 following a July 2026 review of texpeptide.com. Read the letter on fda.gov | Site responding; FDA warning letter Aug 24 2026 | |
| Gram Peptidesgrampeptides.com | FDA warning letter 721806: products including “Retatrutide” (“GLP-1-R peptide”), “Tirzepatide” and “Bacteriostatic Water for Injection” called unapproved new drugs despite “Research Use Only” labeling. Read the letter on fda.gov | Login wall; FDA warning letter Mar 31 2026 | |
| Prime Sciencesprime-sciences.com | FDA warning letter 721805: website reviewed January to March 2026; “laboratory research purposes only” statements did not change the products' status. Read the letter on fda.gov | Login wall; FDA warning letter Mar 31 2026 |
2025
1 letters| Date | Seller | What the letter says | Status log |
|---|---|---|---|
| USApeptide.comusapeptide.com | FDA warning letter 696885: “Notice of Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet.” Cites claims comparing products to Ozempic, Wegovy and Mounjaro. Read the letter on fda.gov | Site responding; FDA warning letter Feb 26 2025 |
2024
2 letters| Date | Seller | What the letter says | Status log |
|---|---|---|---|
| Summit Research Peptidessummitpeptides.shop | FDA warning letter 695607: website reviewed October 2024; five GLP-1-class products found to be unapproved new drugs despite “RESEARCH USE ONLY” labeling. Read the letter on fda.gov | Domain redirects to parked page; FDA letter Dec 10 2024 | |
| Swiss Chems (Swisschems)swisschems.is | FDA (CDER) warning letter 695663: website reviewed October 2024; “Semaglutide” and “Retatrutide” products found to be unapproved new drugs; social posts cited as evidence of intended use. Read the letter on fda.gov | Site responding; FDA warning letter Dec 10 2024 |
How this list is built
We add a letter only after reading it on fda.gov. The list covers sellers in our vendor status log, so it is not every letter FDA has issued. To check any company yourself, search FDA's warning letter index. Spotted an error? See corrections.